Biotech News

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

Pacira BioSciences (PCRX)Pacira BioSciences2026-06-30 11:30 ESTCompany update

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity program -- -- Supports 5x30 strategy and advances Pacira’s transition into an

Open original release

Related news

PCRXPacira BioSciences2026-07-01 12:00 EST

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

PCRXPacira BioSciences2026-06-25 13:46 EST

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders

PCRXPacira BioSciences2026-06-25 13:46 EST

Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

View all latest news

Pacira BioSciences

Pacira BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PCRXZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

PCRXZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

PCRXBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

PCRXGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

PCRXMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 25.54 USD
Market cap: 1B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States